» Articles » PMID: 27028808

[The Biological Function of SHP2 in Human Disease]

Overview
Journal Mol Biol (Mosk)
Publisher Izdatelstvo Nauka
Date 2016 Mar 31
PMID 27028808
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Tyrosyl phosphorylation participates in various pathological and physiological processes, which are regulated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). The Src homology-2 domain containing phosphatase SHP2 (encoded by PTPN11) is an important phosphatase, which was found to be implicated in the regulation of genetic disease, development, metabolic, neurological, muscle, skeletal disease and cancer. Germline mutations in PTPN11 cause the Noonan Syndrome, LEOPARD syndrome and metachondromatosis. Somatic PTPN11 mutations occur in hematologic malignancies and in solid tumors. SHP2 is also an important component in oncogenic signaling pathways. It may play different roles in different stages and positions of human cancers. Whether SHP2 is an oncogene or cancer suppressor gene remains to be elucidated. Elucidation of the regulatory mechanisms of SHP2 in human disease will provide new insights into disease and new targets for therapy. Here, we summarized the structural basis and recent research progression on SHP2 in various human disease, including genetic and cancer diseases.

Citing Articles

Atomistic ensemble of active SHP2 phosphatase.

Anselmi M, Hub J Commun Biol. 2023; 6(1):1289.

PMID: 38129686 PMC: 10739809. DOI: 10.1038/s42003-023-05682-5.


Targeting Src homology phosphatase 2 ameliorates mouse diabetic nephropathy by attenuating ERK/NF-κB pathway-mediated renal inflammation.

Yu C, Li Z, Nie C, Chang L, Jiang T Cell Commun Signal. 2023; 21(1):362.

PMID: 38110973 PMC: 10729421. DOI: 10.1186/s12964-023-01394-9.


Targeting SHP2 phosphatase in hematological malignancies.

Kanumuri R, Pasupuleti S, Burns S, Ramdas B, Kapur R Expert Opin Ther Targets. 2022; 26(4):319-332.

PMID: 35503226 PMC: 9239432. DOI: 10.1080/14728222.2022.2066518.


Strategies to overcome drug resistance using SHP2 inhibitors.

Liu M, Gao S, Elhassan R, Hou X, Fang H Acta Pharm Sin B. 2022; 11(12):3908-3924.

PMID: 35024315 PMC: 8727779. DOI: 10.1016/j.apsb.2021.03.037.


The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation.

Anselmi M, Hub J Proc Natl Acad Sci U S A. 2021; 118(17).

PMID: 33888588 PMC: 8092557. DOI: 10.1073/pnas.2025107118.